A method for lowering TGFß in injured musculoskeletal tissues through the use of TGFß inhibiting antisense oligonucleotides (AO) that enables improved regeneration of dystrophic skeletal muscles. TGFß inhibiting AO, when used in combination with a Dystrophin upregulating AO, enhances restoration of Dystrophin protein expression in the dystrophic muscles.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/12 - Gènes codant pour des protéines animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A securement assembly for a medical catheter inserted into a human body, including an assembly body and a domed cap removably coupled to the assembly body, the domed cap having a first half and an opposing second half, the first half and the second half being coupled together to form a channel inside the domed cap terminating at an opening in the domed cap, the channel being configured to secure the medical catheter, and the assembly body securing an area of the human body surrounding the insertion site of the medical catheter.
A method for improving neurobehavioral outcomes in neonates or infants undergoing cardiac bypass surgery by administering BM-MSCs, BM-MSC derived exosomes, or BM-MSC miRNA into CPB bypass circuit. Compositions comprising BM-MSCs or their products such as exosomes or miRNA are also aspects of the invention as is a kit suitable for performing the methods disclosed herein.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
5.
METHOD AND DEVICE FOR MEASURING AND MONITORING CHILD GROWTH
A measurement system for assessing growth of a patient, including a horizontal platform having a length and a width; a length measuring device including a headboard and at least one footboard, the headboard and the at least one footboard being coupled to the horizontal platform along the length of the horizontal platform; one or more load cells in contact with the horizontal platform; a retractable measuring tape spooled around a cartridge having a rotatable axis; and processing circuitry configured to determine a height of the patient based on a distance between the headboard and the at least one footboard, a weight of the patient based on a weight applied to the one or more load cells, and a head circumference of the patient based on an exposed length of the retractable measuring tape.
A61B 5/107 - Mesure de dimensions corporelles, p. ex. la taille du corps entier ou de parties de celui-ci
G01G 19/50 - Appareils ou méthodes de pesée adaptés à des fins particulières non prévues dans les groupes pour peser des personnes ayant des dispositifs de mesure supplémentaires, p. ex. pour mesurer la taille
6.
TARGETING APOE ENHANCES T-CELL KILLING IN CANCER IMMUNOTHERAPY
The present disclosure provides methods for treating an apoE-expressing cancer, e.g., melanoma, by inhibiting expression or activity of apoE. In certain aspects, the methods prevent immunosuppression induced by apoE secreted by cancer cells, and enhance anti-tumor response by endogenous or adoptively transferred immune cells. The methods provided herein can be used with other therapy, including immunotherapy, such as immunotherapy using checkpoint inhibitors.
A method for automated discrimination between Group A Streptococcus (GAS) and non-GAS pharyngitis, including segmenting and tracking a region of interest including a throat in a displayed image or video; automatically acquiring an input image based on the segmentation of the displayed image or video; receiving at least one patient symptom; removing shadows in the input image; segmenting the input image to isolate the region of interest including the throat; determining an image quality of the isolated region of interest; and classifying, via a machine learning classifier, pharyngitis in the isolated region of interest as being caused by GAS or a non-GAS cause based on the isolated region of interest and the at least one patient symptom.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A method for predicting a severity and appearance of renal obstruction, including receiving, via processing circuitry, a plurality of medical images corresponding to a kidney of a patient, identifying, the kidney in the plurality of medical images, selecting, at least one relevant image from the plurality of medical images based on a relationship to renal function, standardizing the at least one relevant image, determining, via a deep learning model at least one risk score based on the at least one relevant image, and determining, a final ultrasound-based risk score based on the at least one risk score, wherein the final ultrasound-based risk score is a determination of renal obstruction and/or a probability of renal obstruction. Clinical and/or demographic patient information can be used along with the final ultrasound-based risk score to determine a final risk score to predict the severity and appearance of renal obstruction
A laryngoscope, including a blade having a flat top surface and a bottom surface extending from a base of the blade and a first vertical projection and a second vertical projection at the base of the blade extending from the bottom surface of the blade and a connector configured to couple to a handle of the laryngoscope and further configured to couple to the base of the blade via a first opening configured to receive the first vertical projection and a second opening configured to receive the second vertical projection, wherein the base of the blade and a first portion of the blade are transparent or translucent and a second portion of the blade is opaque, and the base of the blade further includes a cutout aligned with a channel in the connector between the first opening and the second opening when the blade is coupled to the connector.
A61B 1/267 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour les voies respiratoires, p. ex. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A digital stethoscope, including a chest piece enclosing a diaphragm; a first microphone configured to acquire a digital auscultation audio signal through the diaphragm and a second microphone configured to acquire an ambient audio signal; and a housing coupled to the chest piece and enclosing processing circuitry, wherein the processing circuitry is configured to generate and output an active noise cancelation signal based on the ambient audio signal, apply a gain to the digital auscultation audio signal, apply a digital filter to the digital auscultation audio signal, and stream the digital auscultation audio signal to external processing circuitry while acquiring the digital auscultation audio signal, and wherein the external processing circuitry is configured to extract a feature of the digital auscultation audio signal and classify the digital auscultation audio signal as including a Still's murmur based on the extracted feature.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
11.
DEVICE FOR SPRAYING CELLS AND POLYMER AND USES THEREOF
A solution blow spin device includes a syringe pump assembly, an airbrush adapter, and a handle base. The syringe pump assembly, airbrush adapter, and handle base are reversibly coupled to one another and configured to work in tandem to address wound dressing using a polymer solution and autologous skin cell suspension co-spray. The airbrush adapter includes multiple nozzles for deposition of multiple solutions sequentially or simultaneously in order to improve would dressing efficacy. The syringe pump assembly includes multiple syringes holding the multiple solutions, and the syringes can be emptied by individually addressable lead screws configured to translate blocks to depress syringe plungers when the lead screws are rotated via corresponding actuators.
A wearable apparatus, including a sound sensor configured to acquire an audio signal from a throat of a wearer; a strain gauge coupled to a flexible band and configured to measure a strain of the strain gauge when the flexible band is in contact with a chest of the wearer during a respiratory cycle of the wearer and output a respiratory signal corresponding to the strain; and processing circuitry contained in a housing and configured to synchronize acquisition of the audio signal and acquisition of the respiratory signal, receive the audio signal from the sound sensor and the respiratory signal from the strain gauge, and transmit the audio signal and the respiratory signal to external processing circuitry.
Aspects of the disclosure provide a connection protector and a securement system including the connection protector. For example, the connection protector can include a first cover portion and a second cover portion, a combination of which forms an internal compartment configured to enclose a connection point of a first conveying device and a second conveying device. A hinge can be coupled to first sides of the first and second cover portions, enabling the first and second cover portions to be in open or close position. Two openings can be formed on both ends of the first and second cover portions, allowing the first and second conveying devices to pass therethrough, respectively. A first tamper-proof locking assembly attached to second sides of the first and second cover portions, the first tamper-proof locking assembly configured to lock the first cover portion to the second cover portion.
An endoscopic device, including an illumination channel; an imaging channel parallel to the illumination channel and having a different longitudinal axis from a longitudinal axis of the illumination channel; a laser diode at a proximal end of the illumination channel and offset from the longitudinal axis of the illumination channel and configured to emit a laser; at least one imaging sensor at a proximal end of the imaging channel and offset from the longitudinal axis of the imaging channel; a laser pathway shifter between the laser diode and the proximal end of the illumination channel and configured to change a propagation direction of the laser; and an imaging pathway shifter between the proximal end of the imaging channel and the at least one imaging sensor and configured to change a propagation direction of light from the imaging channel.
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
15.
DEVELOPMENT OF A BEAT-TO-BEAT FETAL ELECTROCARDIOGRAM
A method for extracting a fetal electrocardiogram (ECG). comprising determining, via processing circuitry, a coherence between a maternal ECG and an abdominal ECG, attenuating, via the processing circuitry, the maternal ECG independent of the coherence, and extracting, via the processing circuitry, the fetal ECG from the abdominal ECG based on the coherence and the attenuated maternal ECG.
A method for determining a burn percentage of a patient, including presenting, via processing circuitry, an image of at least one segment of a body, receiving, via the processing circuitry, a burn indication representing areas within the at least one segment of the body that have sustained a burn, determining, via the processing circuitry, a burned percentage of the at least one segment of the body based on the burn indication, determining, via the processing circuitry, a surface area of the at least one segment of the body based on an age of the patient and a weight of the patient, and determining, via the processing circuitry, the burn percentage of the patient based on the burned percentage of the at least one segment of the body and the surface area of the at least one segment of the body.
A microfluidic device including a first chamber connected to a second chamber by a network of fluid gradient channels; and a pressure-balancing channel connecting a first well to a second well, wherein the first well overlaps with a port of the first chamber and the second well overlaps with a port of the second chamber, and a fluidic resistance of the pressure-balancing channel is less than a fluidic resistance of each fluid gradient channel of the fluid gradient channels.
A gastrostomy tube for insertion through an abdomen and into a stomach, including a cylindrical outer tube including a first proximal opening and a first distal opening, a flange surrounding the first proximal opening of the outer tube, a detachable cylindrical inner tube including a second proximal opening and a second distal opening, and one or more spokes attached to a distal end of the gastrostomy tube, wherein the one or more spokes include an actuatable portion configured to rotate the one or more spokes between a retracted position and an expanded position, wherein the inner tube is insertable into the first proximal opening of the outer tube, wherein the one or more spokes are rotatable into the expanded position when the inner tube is inserted through the first distal opening of the outer tube, and wherein the one or more spokes are substantially perpendicular to the outer tube in the expanded position.
The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.
The present disclosure relates to an isolation gown. In particular, the present disclosure relates to an isolation gown, comprising a garment body including opening running a length of the garment body and terminating at a neck opening, the garment body having a first side and a second side and being configured to permit a wearer to don the medical gown, sleeves extending distally from the garment body, and one or more restraining mechanisms configured to secure the garment body, the sleeves, or a combination thereof, to a body of the wearer, wherein the one or more restraining mechanisms including an actuatable portion utilizing friction to allow the neck opening of the garment body to be contracted to a size of a neck of the wearer, and expanded to be larger than a shoulder width of the wearer.
A method for detecting rheumatic heart disease (RHD) based on at least an echocardiogram, the method including receiving echocardiogram data, extracting first frames corresponding to at least one echocardiogram view from the echocardiogram data, extracting second frames corresponding to ventricular systole from the first frames corresponding to the at least one echocardiogram view, and determining, via at least one machine learning model, an RHD risk score based on the second frames corresponding to ventricular systole.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present invention relates to treating TP53-mutated AML using a Hypoxia-Inducible Factor (HIF inhibitor). The invention further relates to a new HIF inhibitor formulation with longer half-life and significantly improved therapeutic effect for TP53-mutated AML.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
23.
NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USE THEREOF
The present disclosure generally relates target cancer cell specific immunotherapy compositions, methods of making and use thereof. Also provided in the disclosure are methods of treating a cancer in a subject in need thereof.
A method for detecting or monitoring FSHD comprising detecting one or more biomarkers, such as miRNA biomarkers or protein biomarkers that are significantly decreased or increased in subjects having FSHD compared to normal control subjects. Methods for treatment of subjects at risk of having, or having FSHD.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
25.
KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS
The invention described herein provide Kaposi Sarcoma-Associated Herpesvirus (KSHV) oncoprotein antigens and epitopes for expanding antigen-specific T cells. Such expanded T cells are useful for, e.g., in allogeneic or “off-the-shelf” adoptive T cell therapy.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)
Inventeur(s)
Schnermann, Martin John
Kim, Peter C.W.
Cha, Jaepyeong
Nani, Roger Rauhauser
Abrégé
Heptamethine cyanines for use as fluorescent markers of the biliary system are disclosed. Certain heptamethine cyanines exhibit biliary system specificity and methods for in vivo visualization of a biliary system of a subject are provided. The methods may be for diagnostic purposes and/or for visualization of biliary systems during surgery.
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
27.
IMMUNE CELL ENGINEERED WITH IL-8 RECEPTOR AND USE THEREOF
The present invention provides a method for preparing an immune cell, such as a tumor-associated antigen- specific T cell (TAA-T cell), which is engineered with an IL-8 receptor. The present application also provides an immune cell, such as a T cell which is tumor-associated antigen- specific and is engineered with an IL-8 receptor. Immune cells (such as T cells) are genetically engineered to bind to IL-8 in the tumor environment that can serve as a potential strategy to improve immunotherapy for pediatric solid tumors.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
28.
REVERSE-PHASE HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS FOR MEASURING AMINO ACIDS, AMMONIUM, AND GLUTATHIONE CONCENTRATIONS IN BIOLOGICAL SAMPLES
A fast and accurate reverse-phase high pressure liquid chromatography (“RP-HPLC”) method for detecting amino acids in small volumes (e.g. less than 50 µL) of a biological sample, such as plasma. An assay for the simultaneous determination of ammonium and primary amino acids using RP-HPLC in samples such as plasma. A method for calculating intercellular volumes from a cell lysate to which a known volume and concentration of a non-naturally occurring amino acid is added.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
B01D 15/32 - Chromatographie en phase liée, p. ex. avec une phase normale liée, une phase inverse ou une interaction hydrophobe
29.
PREPARATION OF GAMMA L-GLUTAMYL L-CYSTEINE AND BIS GAMMA L-GLUTAMYL CYCSTINE
Provided are compositions and methods that involve viscoelastic poly(lactide-co-caprolactone) (PLCL) mixtures for use in wound healing. The PLCL mixtures provide an improved anti-fibrotic yet tissue-adhesive polymer sealant. The PLCL mixtures can be applied to a variety of wounds arising from surgical and non-surgical tissue damage.
The invention described herein provides a mouse model of BMD (bmx). and uses thereof. The bmx mice of the invention recapitulate several features of BMD and harbour a phenotype intermediate to healthy and Dmd null mdx52 mice. These bmx mice show deficits in muscle and cardiac function, reduced dystrophin protein in skeletal and cardiac muscle, and histopathology consistent with moderate dystrophy.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
32.
ACCESS TOOL FOR DELIVERING CARDIAC THERAPIES TO THE PERICARDIAL SPACE
A surgical access port including an outer sheath having a tapered distal end; an inner sleeve fitting inside the outer sheath; and a cannulated core fitting inside the inner sleeve; wherein a distal opening of the outer sheath is configured to expand when the inner sleeve is inserted into the outer sheath, and wherein the cannulated core forms a first working channel and a second working channel between a first end of the cannulated core and an opposing second end of the cannulated core.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Disclosed are compositions and methods for the diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) using nanopore sequencing and CRISPR/Cas9 enrichment of D4Z4 containing sequences to determine the number of repeats in a D4Z repeat region and methylation of the nucleotide bases in this region.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
35.
IDENTIFICATION OF HLA-RESTRICTED PRAME PEPTIDE EPITOPES, PRAME-SPECIFIC T CELLS SUITABLE FOR "OFF-THE-SHELF" TREATMENT OF CANCER EXPRESSING PRAME
The invention pertains to a method for treating a cancer which expresses PRAME using T cells which recognize specific peptide epitopes of PRAME, to a method for producing T cells that target cancer cells expressing PRAME, the peptide epitopes of PRAME themselves and to compositions and methods of treatment using these peptides.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A securement assembly for a medical catheter inserted into a human body, including an assembly body and a domed cap removably coupled to the assembly body, the domed cap having a first half and an opposing second half, the first half and the second half being coupled together to form a channel inside the domed cap terminating at an opening in the domed cap, the channel being configured to secure the medical catheter, and the assembly body securing an area of the human body surrounding the insertion site of the medical catheter.
e.g.e.g., melanoma, by inhibiting expression or activity of apoE. In certain aspects, the methods prevent immunosuppression induced by apoE secreted by cancer cells, and enhance anti- tumor response by endogenous or adoptively transferred immune cells. The methods provided herein can be used with other therapy, including immunotherapy, such as immunotherapy using checkpoint inhibitors.
A method for extracting a fetal electrocardiogram (ECG), comprising determining, via processing circuitry, a coherence between a maternal ECG and an abdominal ECG, attenuating, via the processing circuitry, the maternal ECG independent of the coherence, and extracting, via the processing circuitry, the fetal ECG from the abdominal ECG based on the coherence and the attenuated maternal ECG.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
39.
DURABLE IMPLANTABLE NON-OBSTRUCTIVE VENOUS ASSIST DEVICE FOR SUPPORT OF CAVOPULMONARY FONTAN CIRCULATION
The circulation assist devices disclosed herein can be used, for example, in methods of decreasing venous pressure in the Fontan circulation. The devices can include an inlet, an outlet, a stator, a rotor, and an impeller driven by rotation of the rotor. In some embodiments, the impeller blade (or blades) can at least partially define a central lumen extending through the device. The device can be coupled to the inferior vena cava and the pulmonary artery. Rotating the impeller blade(s) increases blood velocity through the lumen and causes the outlet pressure to be higher than the inlet pressure. The impeller can be configured such that, when it is stationary, the forward static pressure drop between the inlet and the outlet is minimized. That is, the forward static pressure drop of the device approximates the pressure drop between the inferior vena cava and central pulmonary artery of the unassisted Fontan circulation.
A61M 60/148 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables par, dans, à l’intérieur, en ligne, se ramifiant dans ou autour d’un vaisseau sanguin en ligne avec un vaisseau sanguin par résection ou techniques analogues, p. ex. dispositifs permanents d’assistance cardiaque endovasculaire
A61M 60/35 - Leurs finalités médicales étant autres que l’amélioration du débit cardiaque pour opérations chirurgicales spécifiques, p. ex. procédure de Fontan
A61M 60/422 - Détails concernant l’entraînement des pompes pour le sang à déplacement non positif la force agissant sur l’élément en contact avec le sang étant électromagnétique, p. ex. en utilisant des pompes à moteur à gaine
A61M 60/824 - Paliers hydrodynamiques ou type film de fluide
A61M 60/827 - Dispositifs d’étanchéité entre parties mobiles
A61M 60/237 - Pompes pour le sang à déplacement non positif comportant un élément rotatif agissant sur le sang, p. ex. un impulseur le flux de sang à travers l’élément rotatif ayant des composants principalement axiaux, p. ex. pompes à écoulement axial
40.
T-CELL EPITOPES OF HUMAN PARAINFLUENZA VIRUS 3 FOR ADOPTIVE T-CELL IMMUNOTHERAPY
Disclosed are compositions of T-cells, libraries of such T-cells, and methods of making T-cell subpopulations for treatment of human parainfluenza virus (HPIV) infections, particularly HPIV type 3 (HPIV3) infections. Also disclosed are T-cell compositions comprising cell subpopulations stimulated with HPIV3 antigens and T cell banks containing these compositions for off-the-shelf availability of T cells for treatment of disease.
C07K 14/115 - Paramyxoviridae, p. ex. virus para-influenza
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention provides a method for the detection of viable microorganisms in urine using DNA-crosslinking agent to differentiate between dead and live microorganisms. The DNA-crosslinking agent can penetrate cells which have compromised cell membranes, such as dead cells. The method of the present application comprises amplifying DNA in the urine sample which is pre-treated with the DNA-crosslinking agent. In addition, the method includes the step of centrifugation to remove supernatant from the urine.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
Disclosed are compositions of cells, libraries of such cells and methods of making T cell populations for treatment of disorders such as cancer and viral infections. T cell composition comprise cell subpopulations stimulated, in some embodiments, with FRAME, survivin and/or WT1.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
43.
T-CELL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
The United States of America, as represented by the Secretary, Dept. of Health and Human Service (USA)
Inventeur(s)
Keller, Michael
Bollard, Catherine Mary
Hanajiri, Ryo
Sani, Gelina
Green, Lisbeth Kim
Cohen, Jeff
Sosnovtsev, Stanislav V.
Abrégé
The present disclosure provides adoptive T-cell compositions, therapies, and processes of manufacture that are tailored for treatment or prevention of a subject with a norovirus infection, and, in some embodiments, for those subjects who are candidates for hematopoietic stem cell treatments, subjects who have undergone hematopoietic stem cell treatments, and subjects that have, are diagnosed with or suspected of having primary immunodeficiency disorders.
Disclosed herein are compositions for treating a subject with ischemia reperfusion injury or at risk of developing ischemia reperfusion injury, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. Also disclosed are methods and compositions for treating a subject with sepsis or at risk of developing an infection or sepsis, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. In one embodiment, the agonist of nicotinic cholinergic receptor α7nAchR is varenicline.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
45.
BURN INJURY MANAGEMENT USING A CALCULATION OF TOTAL BODY SURFACE AREA BURNED
A method for determining a burn percentage of a patient, including presenting, via processing circuitry, an image of at least one segment of a body, receiving, via the processing circuitry, a burn indication representing areas within the at least one segment of the body that have sustained a burn, determining, via the processing circuitry, a burned percentage of the at least one segment of the body based on the burn indication, determining, via the processing circuitry, a surface area of the at least one segment of the body based on an age of the patient and a weight of the patient, and determining, via the processing circuitry, the burn percentage of the patient based on the burned percentage of the at least one segment of the body and the surface area of the at least one segment of the body.
A gastrostomy tube for insertion through an abdomen and into a stomach, including a cylindrical outer tube including a first proximal opening and a first distal opening, a flange surrounding the first proximal opening of the outer tube, a detachable cylindrical inner tube including a second proximal opening and a second distal opening, and one or more spokes attached to a distal end of the gastrostomy tube, wherein the one or more spokes include an actuatable portion configured to rotate the one or more spokes between a retracted position and an expanded position, wherein the inner tube is insertable into the first proximal opening of the outer tube, wherein the one or more spokes are rotatable into the expanded position when the inner tube is inserted through the first distal opening of the outer tube, and wherein the one or more spokes are substantially perpendicular to the outer tube in the expanded position.
In an embodiment, the present disclosure relates to a system for performing arthrography, comprising a physical grid positioned on skin of a patient proximate a region of interest of a joint on which the arthrography is to be performed, and processing circuitry configured to receive medical images of the patient, the received medical images being acquired by a same imaging modality and having visible a portion of the physical grid, determine a trajectory between an entry point identified on the physical grid and a target point identified within the region of interest of the joint, and generate a target entry angle based on the determined trajectory between the identified entry point and the identified target point, wherein a needle guide device, configured to releasably-hold a needle, is positionable according to the identified entry point and target entry angle.
A method for predicting a severity and appearance of renal obstruction, including receiving, via processing circuitry, a plurality of medical images corresponding to a kidney of a patient, identifying, the kidney in the plurality of medical images, selecting, at least one relevant image from the plurality of medical images based on a relationship to renal function, standardizing the at least one relevant image, determining, via a deep learning model at least one risk score based on the at least one relevant image, and determining, a final ultrasound-based risk score based on the at least one risk score, wherein the final ultrasound-based risk score is a determination of renal obstruction and/or a probability of renal obstruction. Clinical and/or demographic patient information can be used along with the final ultrasound-based risk score to determine a final risk score to predict the severity and appearance of renal obstruction
The present disclosure relates to an isolation gown. In particular, the present disclosure relates to an isolation gown, comprising a garment body including opening running a length of the garment body and terminating at a neck opening, the garment body having a first side and a second side and being configured to permit a wearer to don the medical gown, sleeves extending distally from the garment body, and one or more restraining mechanisms configured to secure the garment body, the sleeves, or a combination thereof, to a body of the wearer, wherein the one or more restraining mechanisms including an actuatable portion utilizing friction to allow the neck opening of the garment body to be contracted to a size of a neck of the wearer, and expanded to be larger than a shoulder width of the wearer.
This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
Disclosed herein are compositions that inhibit adipogenesis of a fibro/adipogenic precursor (FAP) cell and methods relating to treating, preventing, reducing, and/or inhibiting a muscular degenerative condition a muscular degenerative condition comprising administering said inhibitors.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
52.
CD80 and CD86 binding protein compositions and uses thereof
This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
53.
NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USES THEREOF
The present disclosure generally relates target cancer cell specific immunotherapy compositions, methods of making and use thereof. Also provided in the disclosure are methods of treating a cancer in a subject in need thereof.
Aspects of the disclosure provide a connection protector and a securement system including the connection protector. For example, the connection protector can include a first cover portion and a second cover portion, a combination of which forms an internal compartment configured to enclose a connection point of a first conveying device and a second conveying device. A hinge can be coupled to first sides of the first and second cover portions, enabling the first and second cover portions to be in open or close position. Two openings can be formed on both ends of the first and second cover portions, allowing the first and second conveying devices to pass therethrough, respectively. A first tamper-proof locking assembly attached to second sides of the first and second cover portions, the first tamper-proof locking assembly configured to lock the first cover portion to the second cover portion.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
56.
Solution Blow Spun Polymer Constructs, Compositions and Methods of Fabrications and Uses Relating Thereto
The present disclosure relates to a biocompatible composition comprising a solution of low molecular weight polymer and high molecular weight polymer. The present disclosure also relates to biocompatible compositions comprising poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG), and additionally including a suspension of silica particles and/or a therapeutic agent. The present disclosure is also directed to biocompatible polymer fiber constructs formed from the disclosed compositions, methods of fabrication thereof, and uses of such constructs and compositions.
The disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture. In some embodiments, the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines or functional fragments or variants thereof. The disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.
A method for detecting or monitoring FSHD comprising detecting one or more biomarkers, such as miRNA biomarkers or protein biomarkers that are significantly decreased or increased in subjects having FSHD compared to normal control subjects. Methods for treatment of subjects at risk of having, or having FSHD.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
59.
CIRCULATING MIRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY
A method for detecting or monitoring FSHD comprising detecting one or more biomarkers, such as miRNA biomarkers or protein biomarkers that are significantly decreased or increased in subjects having FSHD compared to normal control subjects. Methods for treatment of subjects at risk of having, or having FSHD.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
60.
SYSTEM AND METHOD FOR INTRAOPERATIVE, NON-INVASIVE NERVE IDENTIFICATION USING SNAPSHOT POLARIMETRY
The present disclosure relates to non-invasive nerve identification using snapshot polarimetry. The present disclosure further relates to a system for nerve identification, the system comprising a camera including a sensor, and a filter having a linear polarizer array, an illumination system configured to illuminate a target area with polarized light illumination, the polarized light illumination having at least one predetermined polarization angle, the illumination system including one more light sources, and one or more polarizer filters, and a processor configured to process imaging data obtained from the camera, and output a birefringence map of the target area including indicia of a nerve structure.
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
61.
WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF
Compositions and methods for the treatment of cancer are provided. Specifically, the disclosure provides a method for treating and/or inhibiting cancer or neoplasia in a subject, the method comprises contacting cancer cells obtained from the subject to be treated with an inhibitor of an immunity suppressing tumor protein; rendering the cancer cells proliferation-incompetent (e.g., by irradiation); and administering the treated cancer cells and a checkpoint inhibitor to the subject, wherein the inhibitor of an immunity suppressing tumor protein is an inhibitor of Inhibitor of differentiation protein 2 (Id2), Myc, and/or apolipoprotein E (ApoE).
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
62.
Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
SARS-CoV-2 causes pandemic COVID19. Developing an effective treatment to directly target the virus could significantly impact viral burden in those most vulnerable to the devastating effects of this virus. The invention provides antisense oligonucleotides (AOs) to target the single stranded RNA genome of the SARS-CoV-2 viruses. The administration of AOs can significantly reduce the target viral RNAs.
The disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture. In some embodiments, the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines (or functional fragments or variants thereof). The disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.
Provided herein are activated adoptive T-cell compositions targeting plasma cell dyscrasias such as multiple myeloma and methods of treating plasma cell dyscrasias such as multiple myeloma using such compositions. The T-cell compositions of the present disclosure are activated against a select group of antigens associated with multiple myeloma (MMAAs) and, in certain embodiments, in combination with more widely expressed tumor associated antigens (TAAs). In particular, the T-cell compositions of the present disclosure are directed to the MMAAs selected from B-cell maturation antigen (BCMA), X box Protein 1 (XBP1), CS1, and Syndecan-1 (CD 138), or a combination thereof. In certain embodiments, the T-cell composition includes T-cells activated to a TAA selected from preferentially expressed antigen of melanoma (PRAME), Survivin, Wilms' Tumor 1 protein (WT1), and melanoma antigen 3 (MAGE-A3), or a combination thereof.
The disclosure provides T-cell compositions, therapies and processes of manufacture that are tailored to the specific antigenic expression of a subjects' tumor and allowing for changes in expression over time based on either pressure from antineoplastic therapy or natural heterogeneous selection. The disclosure also extends to methods of manufacturing such T-cell compositions and the generation of single antigen T-cell banks from healthy donors to provide an improved personalized T-cell therapy.
The present disclosure relates to genetically modified T-cells to secrete broadly neutralizing antibodies against HIV, and methods of preparing and uses thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.
Disclosed are compositions and methods for the diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) using nanopore sequencing and CRISPR/Cas9 enrichment of D4Z4 containing sequences to determine the number of repeats in a D4Z repeat region and methyiation of the nucleotide bases in this region.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
71.
IDENTIFICATION OF HLA-RESTRICTED PRAME PEPTIDE EPITOPES, PRAME-SPECIFIC T CELLS SUITABLE FOR "OFF-THE-SHELF" TREATMENT OF CANCER EXPRESSING PRAME
The invention pertains to a method for treating a cancer which expresses PRAME using T cells which recognize specific peptide epitopes of PRAME, to a method for producing T cells that target cancer cells expressing PRAME, the peptide epitopes of PRAME themselves and to compositions and methods of treatment using these peptides.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
72.
GENETIC DIAGNOSTIC TOOL FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
Disclosed are compositions and methods for the diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) using nanopore sequencing and CRISPR/Cas9 enrichment of D4Z4 containing sequences to determine the number of repeats in a D4Z repeat region and methyiation of the nucleotide bases in this region.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
73.
SYSTEM OF CELL EXPANSION AND METHODS OF USING THE SAME
The present disclosure relates, at least in part, to a closed and semi-automated system for the isolation of naive T cells, their expansion, and/or final harvest. The disclosure also relates to using those isolated cells in a large batch format for compiling stocks of stimulated CD45A+ T cells and/or using the stimulated CD45A+ T cells for therapeutic purposes.
The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.
The present disclosure relates, at least in part, to mycobacterial polynucleotides and polypeptides, to fragments or variants thereof, to cells comprising the mycobacterial polynucleotides and polypeptides, to cells comprising the mycobacterial polynucleotides and polypeptides, that are engineered to expand T-cells ex vivo, and to methods of use thereof.
A visualization system, an apparatus, and a visualization method are provided. The visualization system includes a laparoscope, a camera operatively coupled to the laparoscope, a light source operatively coupled to an illumination port of the laparoscope, and processing circuitry. The light source is configured to output one or more light beams each at a predetermined frequency to illuminate a target area. The processing circuitry is configured to process imaging data from the laparoscope received by the camera to generate one or more images of the target area including at least one laser speckle contrast image. The laparoscope is configured to output the one or more light beams toward the target area at a distal end thereof and to collect reflected and/or scattered light from the target area via the distal end.
A61B 1/313 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour l'introduction dans des incisions chirurgicales, p. ex. laparoscopes
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p. ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
77.
GENERATING VIRUS OR OTHER ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION
Safe, rapid and efficient methods for producing virus-specific or other antigen-specific T-cells from cord blood and other samples containing naive immune cells.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
79.
IMPROVED CELL THERAPY COMPOSITIONS FOR HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
The present disclosure provides for isolated and processed cell therapeutic compositions and Methods of using those compositions for the treatment of a patient undergoing a hematopoietic stem cell transplant (HSCT). In some embodiments, the disclosure provides for methods of making these cells by exposing the isolated T cell populations to one or more tumor antigens.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure provides a system and method for controlling an articulating member including a tool. The method includes determining a first confidence indicator based on a manual control mode for the articulating member, determining a second confidence indicator based on an autonomous control mode for the articulating member, generating an allocation function based on the first confidence indicator and the second confidence indicator, and generating a control command for the articulating member based on the allocation function.
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
The circulation assist devices disclosed herein can be used, for example, in methods of decreasing venous pressure in the Fontan circulation. The devices can include an inlet, an outlet, a stator, a rotor, and an impeller driven by rotation of the rotor. In some embodiments, the impeller blade (or blades) can at least partially define a central lumen extending through the device. The device can be coupled to the inferior vena cava and the pulmonary artery. Rotating the impeller blade(s) increases blood velocity through the lumen and causes the outlet pressure to be higher than the inlet pressure. The impeller can be configured such that, when it is stationary, the forward static pressure drop between the inlet and the outlet is minimized. That is, the forward static pressure drop of the device approximates the pressure drop between the inferior vena cava and central pulmonary artery of the unassisted Fontan circulation.
A61M 60/126 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables par, dans, à l’intérieur, en ligne, se ramifiant dans ou autour d’un vaisseau sanguin
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
A61M 60/00 - Pompes pour le sangDispositifs pour l'actionnement mécanique de la circulationPompes à ballon d’assistance circulatoire
A61M 60/122 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient
A61M 60/135 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables par, dans, à l’intérieur, en ligne, se ramifiant dans ou autour d’un vaisseau sanguin à l’intérieur d’un vaisseau sanguin, p. ex. par greffe
82.
T-CELL EPITOPES OF HUMAN PARAINFLUENZA VIRUS 3 FOR ADOPTIVE T-CELL IMMUNOTHERAPY
Disclosed are compositions of T-cells, libraries of such T-cells, and methods of making T-cell subpopulations for treatment of human parainfluenza virus (HPIV) infections, particularly HPIV type 3 (HPIV3) infections. Also disclosed are T-cell compositions comprising cell subpopulations stimulated with HPIV3 antigens and T cell banks containing these compositions for off-the-shelf availability of T cells for treatment of disease.
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
83.
Generating HPV antigen-specific cells from a naive T cell population
The present disclosure relates to an apparatus and method for correcting rotational error during use of an oblique-viewing endoscope. Specifically, the present disclosure relates to a fast calibration process wherein a new approach is employed in estimating a center of rotation of a plane of an image. Moreover, the approach, allows for updating of a camera matrix during use.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p. ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
86.
METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ISCHEMIA REPERFUSION INJURY AND INFECTION
Disclosed herein are compositions for treating a subject with ischemia reperfusion injury or at risk of developing ischemia reperfusion injury, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. Also disclosed are methods and compositions for treating a subject with sepsis or at risk of developing an infection or sepsis, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. In one embodiment, the agonist of nicotinic cholinergic receptor α7nAchR is varenicline.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)
Inventeur(s)
Schnermann, Martin John
Kim, Peter C. W.
Cha, Jaepyeong
Nani, Roger Rauhauser
Abrégé
Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
C07D 209/10 - IndolesIndoles hydrogénés avec des radicaux hydrocarbonés substitués liés aux atomes de carbone de l'hétérocycle
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
88.
T-CELL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
The present disclosure provides adoptive T-cell compositions, therapies, and processes of manufacture that are tailored for treatment or prevention of a subject with a norovirus infection, and, in some embodiments, for those subjects who are candidates for hematopoietic stem cell treatments, subjects who have undergone hematopoietic stem cell treatments, and subjects that have, are diagnosed with or suspected of having primary immunodeficiency disorders.
The present disclosure provides a system and method for controlling an articulating member including a tool. The system may include a dual camera system that captures near-infrared (NIR) images and point cloud images of a tissue or other substance that includes NIR markers. The system may generate a three-dimensional (3D) path based on identified positions of the NIR markers, may filter the generated path, and may generate a 3D trajectory for controlling the articulated arm of a robot having a tool to create an incision along the filtered path. In a shared control mode, an operator may generate manually control commands for the robot to guide the tool along such a path, while automated control commands are generated in parallel. One or more allocation functions may be calculated based on calculated manual and automated error models, and shared control signals may be generated based on the allocation functions.
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
A61B 34/32 - Robots chirurgicaux opérant de façon autonome
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61B 18/16 - Électrodes neutres ou passives pour mise à la terre
90.
SYSTEM, METHOD, AND DEVICE FOR PERFORMING ARTHROGRAPHY
In an embodiment, the present disclosure relates to a system for performing arthrography, comprising a physical grid positioned on skin of a patient proximate a region of interest of a joint on which the arthrography is to be performed, and processing circuitry configured to receive medical images of the patient, the received medical images being acquired by a same imaging modality and having visible a portion of the physical grid, determine a trajectory between an entry point identified on the physical grid and a target point identified within the region of interest of the joint, and generate a target entry angle based on the determined trajectory between the identified entry point and the identified target point, wherein a needle guide device, configured to releasably-hold a needle, is positionable according to the identified entry point and the target entry angle.
The present invention provides isolated cell compositions for the treatment of cancer, including hematological and solid tumors, comprising a selected, fixed ratio of multiple ex vivo activated lymphocytic cell subsets, including specific immune effector cells directed to specific tumor associated antigens (TAAs), viral associated tumor antigens (VATA), glycolipids, or a combination thereof. By selecting specific fixed ratios of different lymphocytic cell subsets, an immune response which is comprehensive and broad pin biological and immune effector function is provided, enhancing the ability of the administered cells to mount an effective and robust immune response.
The present disclosure is related to a method and apparatus for determining drug usage or a physiological characteristic of a patient. The present disclosure describes acquiring a video sequence, of an eye of a patient, the video sequence being a plurality of video frames, determining a frequency spectrum from a pupillary data of the video sequence, and determining, based on the frequency spectrum, the physiological characteristic or drug of use of the patient. In an embodiment, at least one frequency can be probed based on which physiological characteristic is being explored.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 3/11 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille
A61B 3/14 - Dispositions spécialement adaptées à la photographie de l'œil
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
93.
Apparatus and method for the non-invasive detection of tetrahydrocannabinol use and impairment
The present disclosure is related to a method and apparatus for determining THC usage of a person. The present disclosure describes acquiring a video sequence, of an eye of a patient, the video sequence being a plurality of video frames, determining a frequency spectrum from a pupillary data of the video sequence, and determining, based on the frequency spectrum, the physiological characteristic or drug of use of the patient. In an embodiment, at least one frequency can be probed based on which physiological characteristic is being explored. For example, the physiological characteristic can be Δ#-tetrahydrocannabinol, and the at least one frequency probed can be selected to be specific to Δ#-tetrahydrocannabinol.
G06T 7/70 - Détermination de la position ou de l'orientation des objets ou des caméras
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A61B 3/11 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 70/40 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des médicaments, p. ex. leurs effets secondaires ou leur usage prévu
G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
Disclosed herein are compositions that inhibit adipogenesis of a fibro/adipogenic precursor (FAP) cell and methods relating to treating, preventing, reducing, and/or inhibiting a muscular degenerative condition a muscular degenerative condition comprising administering said inhibitors.
The disclosure provides modified NK cells and pharmaceutical compositions comrpsing the same. The disclosure also provides methods of treating cancer using the same.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
96.
SOFT CYLINDRICAL TORQUE TOOL FOR MEDICAL DEVICES WITH LUMEN
The present disclosure is related to a device for gripping catheters that are used in interventional cardiac procedures without causing internal catheter damage. The present disclosure will allow the operator to maintain improved stability and maneuverability compared with current approaches, including, primarily, digital manipulation, which can lead to fatigue, instability and inappropriate catheter movement. Specifically in the pediatric population where small movements can lead to severe and permanent complications, the present disclosure has the potential to increase the safety profile of already high-risk interventional catheterization and electrophysiology procedures.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
98.
CYTOKINE COCKTAILS FOR SELECTIVE EXPANSION OF T CELL SUBSETS
The disclosure relates to methods of culturing and expanding CD4+ and/or CD8+ T cells in culture. In some embodiments, the methods include expanding, proliferating and storing lymphocytes in tissue culture by exposing the lymphocytes to a combination of cytokines and/or nucleic acids expressing cytokines (or functional fragments or variants thereof). The disclosure further relates to methods of generating and manufacturing CD4+ and/or CD8+ T cells that are specific to one or a plurality of viral antigens.
Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
100.
Gapmers and methods of using the same for the treatment of muscular dystrophy
The Governors of the University of Alberta (Canada)
Inventeur(s)
Chen, Yi-Wen
Yokota, Toshifumi
Yokota-Maruyama, Rika
Echigoya, Yusuke
Abrégé
The disclosure relates to compositions comprising a nucleotide sequence having two domains: a locked nucleic acid (LNA) domain and a DNA gap domain, wherein nucleotide sequence binds to an endogenous DUX4 mRNA sequence disrupts DUX4 expression.
